Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.…
Waverley Pharma (CVE: WAVE) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0100 CAD on 19 November 2026, down 60.0% over 52 weeks. Its 52-week range is 0.0100 CAD to 0.0400 CAD, and it trades at the bottom of that range.
Its market capitalisation is 540.00K CAD.
Waverley Pharma reports return on equity of 19.4%, an operating margin of -47.7% and revenue down 18.4% year over year.
Its debt exceeds its cash by 3.56M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 November 2026.